This work not only deepens scientific insight into ipamorelin's mechanism but also supports its potential as a well-tolerated therapeutic option for conditions requiring growth hormone modulation, paving the way for future clinical applications
Our results can be explained by the well documented biocompatibility of GSH-AuNCs in vitro 29,55 and in vivo 19
Importantly, GLP-2R is not expressed on enterocytes
Research has shown that decreasing NNMT may help shrink fat cells and reduce the size of fat deposits
As many as two-thirds of people using a GLP-1 to lose weight stop taking the drug within a year, citing unpleasant side effects (diarrhea, constipation, nausea and vomiting) and the relatively high cost of the medication
Notably, the use of GLP-1 agonists was higher than expected for over half (59%) of employers with over 5,000 workers